Pfizer and AstraZeneca vaccines were as effective as prior infection, U.K. study finds

Two doses of either the vaccine made by Pfizer (NYS:PFE) and BioNTech (NAS:BNTX) or Oxford-AstraZeneca (NAS:AZN) vaccines provided a similar level of protection to prior natural infection when the Delta variant was dominant, the U.K. Office of National Statistics said Monday . Vaccination significantly reduced the risk of people testing positive during both the Alpha-dominant period and the Delta-dominant period, but effectiveness was reduced in the Delta-dominant period compared with the Alpha-dominant period. The ONS added that two doses of either vaccine provided significantly greater protection than one dose across all analyses.